Pravastatin for preeclampsia: From animal to human.
PlGF
fetal growth restriction (FGR)
pravastatin
preeclampsia
sFLT1
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
28
02
2020
revised:
15
04
2020
accepted:
19
04
2020
pubmed:
3
6
2020
medline:
22
6
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
Preeclampsia is characterized by the emergence of hypertension and proteinuria after 20 weeks of pregnancy, and it threatens both maternal and fetal lives if it proceeds unabated. Despite numerous studies, thus far the only fundamental therapy for preeclampsia is termination of pregnancy, leading to preterm birth. Furthermore, preeclamptic women are reported to be at risk for cardiovascular diseases for 10 years after delivery. Therefore, preventative and therapeutic strategies for preeclampsia are required. Recently, statins have been reported to improve the regeneration of vascular endothelium, and pravastatin has attracted attention as a potential preventative or therapeutic candidate for preeclampsia. Pravastatin has been demonstrated to have preventative effects in preeclampsia model mice, and a large volume of human data from pregnant women taking statins supports the safety of these drugs. Moreover, small clinical trials have reported that pravastatin has strong preventative or therapeutic effects on preeclampsia and it has the potential to improve the prognosis of pregnant women, fetuses and neonates affected by this condition.
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Pravastatin
KXO2KT9N0G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1255-1262Subventions
Organisme : Grant-in-Aid for Scientific Research
ID : 17K11232
Informations de copyright
© 2020 Japan Society of Obstetrics and Gynecology.
Références
Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799.
Roberts JM, Hubel CA. The two stage model of preeclampsia: Variations on the theme. Placenta 2009; 30: S32-S37.
Nakashima A, Yamanaka-Tatematsu M, Fujita N et al. Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia. Autophagy 2013; 9: 303-316.
Berends AL, Bertoli-Avella AM, de Groot CJ, van Duijn CM, Oostra BA, Steegers EA. STOX1 gene in pre-eclampsia and intrauterine growth restriction. BJOG 2007; 114: 1163-1167.
Rolnik DL, Wright D, Poon LC et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613-622.
Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
Costantine MM, Cleary K, Hebert MF et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: A pilot randomized controlled trial. Am J Obstet Gynecol. 2016; 214: 720 e721-720 e717.
Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
Koga K, Osuga Y, Yoshino O et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348-2351.
Nagamatsu T, Fujii T, Kusumi M et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145: 4838-4845.
Suzuki H, Ohkuchi A, Matsubara S et al. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009; 54: 1129-1135.
Mateus J, Bytautiene E, Lu F et al. Endothelial growth factor therapy improves preeclampsia-like manifestations in a murine model induced by overexpression of sVEGFR-1. Am J Physiol Heart Circ Physiol 2011; 301: H1781-H1787.
Costantine MM, Tamayo E, Lu F et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 2010; 116: 114-120.
Saad AF, Diken ZM, Kechichian TB et al. Pravastatin effects on placental Prosurvival molecular pathways in a mouse model of preeclampsia. Reprod Sci 2016; 23: 1593-1599.
Kumasawa K, Ikawa M, Kidoya H et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108: 1451-1455.
Abitbol MM. A simplified technique to produce toxemia in the pregnant dog. Am J Obstet Gynecol 1981; 139: 526-534.
Bauer AJ, Banek CT, Needham K et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension 2013; 61: 1103-1110.
Agostinis C, Bulla R, Tripodo C et al. An alternative role of C1q in cell migration and tissue remodeling: Contribution to trophoblast invasion and placental development. J Immunol 2010; 185: 4420-4429.
Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011; 58: 716-724.
Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS ONE 2010; 5: e13663.
Bertolaccini ML, Contento G, Lennen R et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun 2016; 75: 30-38.
Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996; 10: 439-446.
Girardi G. Can statins prevent pregnancy complications? J Reprod Immunol Mar 2014;101-102:161-167.
Bateman BT, Hernandez-Diaz S, Fischer MA et al. Statins and congenital malformations: Cohort study. BMJ 2015; 350: h1035.
Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: Between supposed risks and theoretical benefits. Drugs 2012; 72: 773-788.
Winterfeld U, Allignol A, Panchaud A et al. Pregnancy outcome following maternal exposure to statins: A multicentre prospective study. BJOG 2013; 120: 463-471.
Cleary KL, Roney K, Costantine M. Challenges of studying drugs in pregnancy for off-label indications: Pravastatin for preeclampsia prevention. Semin Perinatol 2014; 38: 523-527.
Balan A, Szaingurten-Solodkin I, Swissa SS et al. The effects of pravastatin on the normal human placenta: Lessons from ex-vivo models. PLoS ONE 2017; 12: e0172174.
Lefkou E, Mamopoulos A, Fragakis N et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension 2014; 63: e118-e119.
Brownfoot FC, Tong S, Hannan NJ et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension 2015; 66: 687-697 discussion 445.
Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest 2016; 126: 2933-2940.
Ahmed A, Williams DJ, Cheed V et al. Pravastatin for early-onset pre-eclampsia: A randomised, blinded, placebo-controlled trial. BJOG 2020; 127: 478-488.